Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

PDGF-D: a novel target for the treatment of mesangioproliferative glomerulonephritis

Sep. 17, 2003

Potent, orally active and rapid-acting PDE5 inhibitor discovered at Schering-Plough

Sep. 16, 2003

Kyorin patent covers new NK1 antagonists for urinary incontinence and other uses

Sep. 8, 2003

Second approvable letter issued for duloxetine

Sep. 4, 2003

Bayer researchers describe two novel series of Rho kinase inhibitors

Sep. 3, 2003

Levitra receives FDA approval

Aug. 25, 2003

Preliminary results of North American Cystistat trial for interstitial cystitis

Aug. 22, 2003

Improved safety profile for transdermal oxybutynin vs. oral tolterodine in overactive bladder

Aug. 19, 2003

Yamanouchi and GlaxoSmithKline to copromote Vesicare in U.S.

Aug. 13, 2003

Two novel series of VR1 antagonists for urinary incontinence, pain, etc.

Aug. 12, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...